Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy of lenvatinib in patients with non-alcoholic fatty liver dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Tani, Joji, Kariyama, Kazuya, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Yasuda, Satoshi, Toyoda, Hidenori, Aoki, Tomoko, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Arai, Taeang, Okubo, Tomomi, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Koji, Hiasa, Yoichi, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370989/
https://www.ncbi.nlm.nih.gov/pubmed/34404856
http://dx.doi.org/10.1038/s41598-021-96089-x

Ejemplares similares

Ejemplares similares